Robert Meehan
About
Robert Meehan is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Robert Meehan has authored 49 papers receiving a total of 762 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 18 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Robert Meehan's work include Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (10 papers) and Immunotherapy and Immune Responses (9 papers). Robert Meehan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (10 papers) and Immunotherapy and Immune Responses (9 papers). Robert Meehan collaborates with scholars based in United States, Australia and United Kingdom. Robert Meehan's co-authors include Alice P. Chen, James H. Doroshow, Geraldine O’Sullivan Coyne, Joshua P. Frederick, Manish R. Patel, T. Khanh, Lamin Juwara, Shivaani Kummar, Tal Zaks and Kristen Hopson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Robert Meehan
46 papers receiving 742 citations
Peers
Robert Meehan
Huaizu Guo China
Kelly McGlinchey United States
Vladimir Roudko United States
Egle Ramelyte Switzerland
Bernardina T.F. van der Gun Netherlands
J. Charles France
Cecilia Muñoz‐Calleja Spain
René G. Ott Austria
Christopher B. Benton United States
K. Witter Germany
Citations per year, relative to Robert Meehan Robert Meehan (= 1×)
peers
Huaizu Guo
Countries citing papers authored by Robert Meehan
Since
Specialization
Citations
This map shows the geographic impact of Robert Meehan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Meehan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Meehan more than expected).
Fields of papers citing papers by Robert Meehan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Robert Meehan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Meehan. The network helps show where Robert Meehan may publish in the future.
Co-authorship network of co-authors of Robert Meehan
This figure shows the co-authorship network connecting the top 25 collaborators of Robert Meehan. A scholar is included among the top collaborators of Robert Meehan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Meehan. Robert Meehan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ladwa, Rahul, Ann W. Silk, Muhammad A. Khattak, et al.. (2024). 940TiP INTerpath-007: A phase II/III, adaptive, randomized study of neoadjuvant and adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) for treatment of resectable locally advanced (LA) cutaneous squamous cell carcinoma (cSCC). Annals of Oncology. 35. S652–S653.
2.
Choueiri, Toni K., Thomas Powles, David A. Braun, et al.. (2024). 45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma. The Oncologist. 29(Supplement_1). S15–S15.
3.
Weber, Jeffrey S., Jason J. Luke, Matteo S. Carlino, et al.. (2024). INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma.. Journal of Clinical Oncology. 42(16_suppl). TPS9616–TPS9616.
4.
Valderrama, Begoña P., Shilpa Gupta, Maria De Santis, et al.. (2024). 2021TiP INTerpath-005: Phase II study of pembrolizumab (pembro) with V940 (mRNA-4157) versus pembro with placebo (pbo) for adjuvant treatment of resected high-risk muscle-invasive urothelial carcinoma (MIUC). Annals of Oncology. 35. S1164–S1164.
5.
Weber, Jeffrey S., Muhammad Adnan Khattak, Matteo S. Carlino, et al.. (2024). Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.. Journal of Clinical Oncology. 42(17_suppl). LBA9512–LBA9512.
6.
Spicer, Jonathan, Adnan Khattak, Jay M. Lee, et al.. (2024). Abstract CT281: The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC). Cancer Research. 84(7_Supplement). CT281–CT281.
7.
Khattak, Adnan, Jeffrey S. Weber, Tarek Meniawy, et al.. (2023). Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.. Journal of Clinical Oncology. 41(17_suppl). LBA9503–LBA9503.
8.
Mittra, Arjun, Geraldine O’Sullivan Coyne, Jennifer Zlott, et al.. (2023). Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors. Cancer Chemotherapy and Pharmacology. 93(3). 177–189.
9.
Weber, Jeffrey S., Adnan Khattak, Matteo S. Carlino, et al.. (2023). LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response. Annals of Oncology. 34. S1288–S1289.
10.
Powderly, John D., Ryan J. Sullivan, Martin Gutierrez, et al.. (2023). Phase 1/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). TPS2676–TPS2676.
11.
Burris, Howard A., Manish R. Patel, Daniel C. Cho, et al.. (2019). A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 2523–2523.
12.
Meehan, Robert, Shivaani Kummar, T. Khanh, et al.. (2018). A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas. The Oncologist. 23(11). 1269–e125.
13.
Kummar, Shivaani, Geraldine O’Sullivan Coyne, T. Khanh, et al.. (2017). Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). Journal of Clinical Oncology. 35(14). 1561–1569.
14.
Meehan, Robert, Geraldine O’Sullivan Coyne, Shivaani Kummar, et al.. (2017). A phase I trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.. Journal of Clinical Oncology. 35(15_suppl). 2518–2518.
15.
Coyne, Geraldine O’Sullivan, Alice P. Chen, Robert Meehan, & James H. Doroshow. (2017). PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. Drugs. 77(2). 113–130.
16.
Meehan, Robert, Alice P. Chen, & James H. Doroshow. (2016). Role of adaptive randomization in developing novel therapies for patients with breast cancer. Translational Cancer Research. 5(6).
17.
Coyne, Geraldine O’Sullivan, Shivaani Kummar, Jerry M. Collins, et al.. (2016). First-in-human trial of 4'-thio-2'-deoxycytidine (TdCyd) in patients with advanced solid tumors. Annals of Oncology. 27. vi133–vi133.
18.
Meehan, Robert & Alice P. Chen. (2016). New treatment option for ovarian cancer: PARP inhibitors. PubMed. 3(1). 3–3.
19.
Coyne, Geraldine O’Sullivan, Shivaani Kummar, Peter L. Choyke, et al.. (2016). Activity of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis.. Journal of Clinical Oncology. 34(15_suppl). 11028–11028.
20.
Meehan, Robert, David C. Seldin, J. Mark Sloan, et al.. (2016). Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis. Bone Marrow Transplantation. 51(10). 1318–1322.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Huaizu Guo Breakdown of academic impact, for papers by Kelly McGlinchey Breakdown of academic impact, for papers by Vladimir Roudko Breakdown of academic impact, for papers by Egle Ramelyte Breakdown of academic impact, for papers by Bernardina T.F. van der Gun Breakdown of academic impact, for papers by J. Charles Breakdown of academic impact, for papers by Cecilia Muñoz‐Calleja Breakdown of academic impact, for papers by René G. Ott Breakdown of academic impact, for papers by Christopher B. Benton Breakdown of academic impact, for papers by K. Witter